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Background: Breast cancer–endothelium interactions provide regulatory signals facilitating tumor progression.
The endothelial cells have so far been mainly viewed in the context of tumor perfusion and relatively little is
known regarding the effects of such paracrine interactions on the expression of extracellular matrix (ECM),
proteasome activity and properties of endothelial cells.
Methods: To address the effects of breast cancer cell (BCC) linesMDA-MB-231 andMCF-7 on the endothelial cells,
two cell culture models were utilized; one involves endothelial cell culture in the presence of BCCs-derived
conditioned media (CM) and the other co-culture of both cell populations in a Transwell system. Real-time
PCR was utilized to evaluate gene expression, an immunoﬂuorescence assay for proteasome activity, and func-
tional assays (migration, adhesion and invasion) and immunoﬂuorescence microscopy for cell integrity and
properties.
Results: BCC-CMdecreases the cellmigration of HUVEC. Adhesion and invasion of BCCs are favored byHUVEC and
HUVEC-CM. HA levels and the expression of CD44 and HA synthase-2 by HUVEC are substantially upregulated in
both cell culture approaches. Adhesion molecules, ICAM-1 and VCAM-1, are also highly upregulated, whereas
MT1-MMP andMMP-2 expressions are signiﬁcantly downregulated in both culture systems. Notably, the expres-
sion and activity of the proteasome β5 subunit are increased, especially by the action of MDA-MB-231-CM on
HUVEC.
Conclusions and general signiﬁcance: BCCs signiﬁcantly alter the expression of matrix macromolecules, protea-
some activity and functional properties of endothelial cells. Deep understanding of such paracrine interactions
will help to design novel drugs targeting breast cancer at the ECM level. This article is part of a Special Issue
entitled Matrix-mediated cell behaviour and properties.© 2014 Elsevier B.V. All rights reserved.1. Introduction
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997153.
anos).proliferation or evasion of cell death and immune system destruction,
activated invasion and metastasis, induced angiogenesis as well as
reprogrammed energy metabolism that coordinate tumor progression
[1,2]. The importance of the tumor microenvironment is becoming
increasingly appreciated given the fact that tumors are not only
self-sufﬁcient moieties but also recruit normal cells of the underlying
stroma in favor of tumor progression [3–6]. Metastasis represents a
key event of this process that depends on the ability of the cancer
cells to grow, degrade the host stroma,migrate into a complex network
ofmacromolecules; extracellularmatrix (ECM), adhere, possibly transmi-
grate through the endothelium into andout of the blood streamand lastly
invade the tissue where the metastasis will establish.
In the present study, we focused on a crucial player of this reciprocal
relationship between cancer cells and tumor microenvironment, the
endothelial cells. The endothelium is highly specialized and its origin
varies considerably from tissue to tissue and organ to organ [4,7].
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tions and establish active contacts with the endothelium that entail
remarkable cytoskeletal changes prerequisite for trans-endothelial
migration (TEM) into the underlying matrix and stroma [8,9]. Several
cancer cell surface molecules have been documented to counteract
with molecules on the endothelial cell surface. Among them selectins,
integrins, CD44 and the adhesion molecules ICAM, VCAM contribute
in that way to the “docking-locking” hypothesis [9].
It is well established that cellular behavior is highly regulated by
ECM, and as a consequence cancer progression is dependent on its
unique properties, involving alterations in ECM components' structure
and/or expression as well as the activity modiﬁcations that take place
during this process [10,11]. Endothelial glycocalyx represents a nega-
tively charged organized network of ECM macromolecules that lines a
healthy vascular endothelium. This scaffold consists of a variety of
transmembrane- and membrane-attached molecule proteoglycans
(syndecan-1, -2, -4 and glypican-1), as well as cell adhesion molecules
(integrins, selectins), inﬂammatory regulators and adsorbed compo-
nents (coagulation system) [12,13]. In addition secreted proteoglycans
(mimecan, perlecan, and biglycan) reside in the glycocalyx interface
or diffuse into the blood stream [14,15]. Themost prominent glycosami-
noglycan (GAG) incriminated on the surface of endothelial cells is
heparan sulfate (HS) accounting for 50%–90% of the total GAG pool,
and the rest being composed of chondroitin sulfate (CS) and hyaluronan
(HA), with levels depending on cell types [16].
Regardless of its source, the endothelium exerts critical functions in
several aspects of cancer biology including tumor progression, angio-
genesis, and metastasis. It is documented to regulate angiogenesis in
order to provide nutrients, oxygen, and other solutes through the blood-
stream to the tumor, supply of paracrine factors recruiting other stromal
players like immune cells to the tumor site and modulation of cancer
cell dissemination [17,18]. An additional level in the complexity of the
interplay between cancer cells and endothelial cells arises from the dy-
namic interaction of glycocalyx with the local microenvironment as en-
dothelial cells have high rates of continuous metabolic turnover that
allow adaptation to changes [19]. Compelling evidence also suggests
that the glycocalyx on endothelial cells functions as a matrix barrier. It
is well established that tumor cell adhesion to the microvessel wall de-
grades the endothelial surface glycocalyx layer [20]. Taken all together,
cancer cell extravasation is induced by the disruption of this layer by
pro-inﬂammatory cytokines and degrading enzymes produced by can-
cer cells, thereby inﬂuencing vascular endothelial barrier integrity
[21–25]. On the other hand, the endothelial glycocalyx composition is
able to act itself as a positive or negative modulator of cell adhesion to
endothelium. For example, if the size of constituent parts of the endo-
thelial surface layer such as HS proteoglycans and hyaluronan is greater
than the size of adhesion molecules, the adherence of cells is prevented
[26]. On the other hand, endothelial derived hyaluronan serves as ligand
for its adjacent receptor CD44 expressed in cancer cells [27]. Further-
more, endothelial glycocalyx entraps growth factors via the glycosami-
noglycan chains of proteoglycans, increasing in thatway the endothelial
permeability [23]. In addition, it reported that through all of these steps
of active interaction between cancer cells and the endothelium, both
parties undergo critical cytoskeletal changes to facilitate such interplay
[28,29].
Proteasome is a major cellular protease complex that regulates non-
lysosomal degradation, thus in turn controlling the concentration and
turnover of ECM [30]. Several proteasome inhibitors are proposed as
novel anti-cancer agents, exerting anti-tumor activity in vivo. Apart
from its role in cancer cell apoptosis/growth, ubiquitin proteasome
system (UPS) has been indicated in several cases directly or indirectly
to the dys-function of the endothelial front.
The reciprocal interactions between the endothelium and cancer
cells are a complex scenario that is not fully characterized yet. In the
present study, we therefore focus on the evaluation of the effects of
breast cancer cells on the endothelium microtubules and functionalproperties, expression of matrix and cell surface effectors (endothelial
glycocalyx composition) and proteasome activity.2. Materials and methods
2.1. Chemicals and reagents
FBS (fetal bovine serum), DMEM, sodium pyruvate, L-glutamine,
penicillin, streptomycin, amphotericin B and gentamycin were all ob-
tained from Biochrom (Berlin, Germany).2.2. Cell cultures
Human umbilical vein endothelial cells (HUVECs) were purchased
from Lonza (Walkersville, USA) and were grown for 2–6 passages in
EGM2 culture medium (Lonza) supplemented with 2% fetal bovine
serum. The cultures were maintained in an atmosphere of humidiﬁed
95% air, 5% CO2 at 37 °C.
Breast cancer cells of human breast adenocarcinoma, MDA-MB-231
(ATCC® HTB-26) and MCF-7 (ATCC® HTB-22) were obtained from the
American Tissue Culture Collection. Breast cancer cells were cultured
in DMEM supplemented with 10% (v/v) FBS, 1.0 mM sodium pyruvate,
and a cocktail of antimicrobial agents (100 IU/mL penicillin, 100 μg/mL
streptomycin, 10 μg/mL gentamycin sulfate and 2.5 μg/mL amphotericin
B). Cells were routinely grown at 37 °C in a humidiﬁed atmosphere of
5% (v/v) CO2. Culture medium was changed every 48–72 h. Cells were
harvested by trypsinization with 0.05% (w/v) trypsin in PBS containing
0.02% (w/v) Na2EDTA.2.3. Experimental sets
Two experimental approaches were utilized; one involves endothe-
lial cell culture in the presence of breast cancer cell-derived conditioned
media (BCC-CM) and the other co-culture of both cell populations in a
Transwell system using 0.4 μM microporous membrane (Fig. 1). In
some cases the effect on HUVEC CM on breast cancer cells culture was
also evaluated. In the CM experimental approach, the role of the pro-
duced factors under growing conditions and their effect on the adjacent
microenvironment were evaluated. Introducing to our approach the
element of cell–cell communication, the co-culture transwell system
was utilized where breast cancer cells and HUVEC interact and ex-
change soluble factors between the microporous membrane.
HUVEC (BCC-CM approach). Six hours before treatments, subconﬂuent
(ca 70%) HUVECs were cultured in EGM2 with 0.2% fetal bovine serum.
The medium was then changed to EGM2 plus 2% fetal bovine serum
supplemented with equal amount of BCC-CM and incubated for 24 h
(Fig. 1A).
Cancer cells (HUVEC-CM approach). Six hours before treatments,
subconﬂuent breast cancer cells (ca 70%) were cultured in serum free
DMEM. The medium was then changed to DMEM plus 2% fetal bovine
serum supplemented with equal amount of HUVEC-CM and incubated
for 24 h (Fig. 1B).
Conditioned media (BCCs-CM & HUVEC-CM) were generated from
conﬂuent cell monolayers by 24 h of culture in the appropriate culture
medium. Cells and debris were removed by centrifugation (5 min,
500 ×g), and media were aliquoted and stored at−80 °C. In each case
the culture media of the adjacent utilized CMmedia served as negative
control of the experiment.
Transwell approach. HUVEC (lower chamber) and breast cancer cells
(upper chamber) are co-cultured in EGM2 plus 2% and DMEM plus 2%,
respectively using a transwell insert with 0.4 μM microporous mem-
brane. Control HUVEC were cultured in the presence of culture media
of BCCs in the upper chamber. Before the incubation cell monolayers
were serum starved like the CM approach (Fig. 1C).
Fig. 1. Experimental approaches used in this study. (A) Endothelial cell culture in the presence of breast cancer cell-derived conditioned media (CM); (B) Breast cancer cell culture in the
presence of HUVEC-derived conditioned media (CM); (C) Co-culture of both cell populations in a Transwell system using 0.4 μMmicroporous membrane.
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2.4.1. In vitro wound healing assay
HUVEC conﬂuent cell layers were wounded by scratching with a
sterile 10 μL pipette tip. Detached cells were removed by washing two
times with PBS and fresh culture medium was added in the absence or
presence of conditioned media. The wound closure was monitored at
0, 6, 12, 24 h using a digital camera connected to a microscope.
Wound surface area was quantiﬁed by image analysis (ImageJ 1.4.3.67
Launcher Symmetry Software).
2.4.2. Breast cancer cell invasion assay
The invasive potential of breast cancer cells was evaluated using
Transwell inserts [Chemicon (Millipore) QCM™, ECM550]. Each insert
(invasion chamber) bottom possesses an 8-μm pore size polycarbonate
membrane, over which a thin layer of ECMatrixTM is dried. Prior to cell
invasion assay, the cells were treated with or without HUVEC-CM. Cells
(ca 240,000) per invasion chamber in serum-free culture mediumwere
seeded and allowed to invade for 24 h at 37 °C using 10% FBS culture
medium or HUVEC-derived CM as chemo-attractant in the lower cham-
ber. During the incubation a percentage of the cells adhere, invade the
layer of ECM and then migrate to the bottom of the membrane. Non-
invasive cells are removed with a cotton swab and invasive cells are
stained on the lower surface of the membrane with Crystal violet. The
membrane is photographed using a digital camera connected to a
microscope. Then, stained cells are diluted in 10% (v/v) acetic acid and
the color measured with an ELISA plate reader at 560 nm.
2.4.3. Breast cancer cell adhesion assay
Cancer cells were loaded with cell tracker Red CMTPX (Invitrogen,
Milan, Italy) (working solution concentration 10 μΜ) and incubated
for 30 min at growing conditions, according to the manufacturer's in-
structions. Labeled-cancer cells are plated on treated and untreated
HUVEC cell monolayer. HUVEC cell monolayer was pre-treated with
1000 U/mL (1 h 37 °C) of hyaluronidase (Seikagaku Corporation,
Tokyo, Japan) or EDTA buffer (1 mM EDTA pH 7.4, 10 min at 37 °C).After 3 h incubation period and PBS washing, the numbers of adherent
cancer cells on HUVEC cell monolayer were assessed under a ﬂuores-
cent microscope (Olympus, Segrate, Italy).
2.5. RNA isolation and real-time PCR
Total RNA samples were extracted from HUVEC and breast cancer
cells with Trizol (Invitrogen, Milan, Italy). For quantitative RT-PCR,
RNA samples that were previously digested with Turbo DNase
(Ambion, Monza, Italy) were retrotranscribed using the High Capacity
cDNAsynthesis kit (Applied Biosystems, Monza, Italy) and ampliﬁed
on an Abi Prism 7000 instrument (Applied Biosystems, Monza, Italy)
using the Taqman Universal PCR Master Mix (Applied Biosystems)
following the manufacturer's instructions.
The following human TaqMan gene expression assays were
used: CD44 (HS00174139_m1), HAS2 (Hs00193435_m1), ICAM
(Hs00164932), VCAM (Hs00174239), MMP-2 (Hs00234422_m1),
MT1-MMP (Hs00237119_m1), ß5subunit F: GGC AAT GTC GAA
TCT ATG AGC, R: GTT CCC TTC ACT GTC CAC GTA and β-actin
(Hs99999903_m1). Fluorescent signals generated during PCR ampliﬁ-
cations were monitored and analyzed with Abi Prism 7000 SDS soft-
ware (Applied Biosystems). Comparison of the amount of each gene
transcript among different samples was made using RNAseP as the
reference. In order to determine the efﬁciency of each Taqman gene
expression assay, standard curves were generated by serial dilution of
cDNA, and quantitative evaluations of target and housekeeping gene
levels were obtained by measuring threshold cycle numbers (Ct). As
the differences among efﬁciencies of each Taqman gene expression
assay were b0.1, the relative quantiﬁcation of gene expression was
determined by comparing 2−ΔΔCt [31].
2.6. Hyaluronan expression solid phase assay
Thehyaluronan expression of HUVEC in the culturemediumwasde-
termined by Corgenix HA Test kit, a sandwich protein binding solid
phase assay (Corgenix, USA). The concentration of the produced HA
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In turn, the media was assayed according to the manufacturers'
instructions.
2.7. Proteasome activity assay
Chymotrypsin-like activity (β5) was measured using SucLLVY-7-
amido-4-methylcoumarin (AMC). The ﬂuorogenic proteasome substrate
was added to the cell lysate at a ﬁnal concentration of 80 μM in 1%
DMSO. ATP-dependent cleavage activity was monitored continuously
by detection of free 7-amido-4-methylcoumarin using a ﬂuorescence
plate reader at 380/460 nm at 37 °C.
2.8. Immunoﬂuorescence staining of endothelial microtubules
HUVECs were seeded on glass coverslips in 6-well plates and grown
to conﬂuence prior to treatment. Cells were washed twice with PBS
buffer, ﬁxed in 4% formaldehyde in PBS buffer, washed three times
with PBS-Tween buffer, permeabilized with freshly made 0.5% Triton
X-100 in PBS, washed three times with PBS-Tween buffer and blocked
with 5% BSA in PBS-Tween. Endothelial microtubules were visualized
(×60 magniﬁcation) by immunoﬂuorescence staining using a mouse
monoclonal antibody against α-tubulin (1:100; Sigma) and an Alexa
Fluor 594 anti-mouse second antibody (1:2000; Invitrogen), and
the coverslips were mounted on microscope slides. Alterations in
HUVEC microtubule morphology were assessed by comparison of
photographs of control and treated endothelial cells from three individual
experiments.
2.9. Statistical analysis
In all experiments, the mean values ± standard deviations (SD) for
determinations in triplicate were calculated. Statistically signiﬁcant
differences were evaluated using the ANOVA test. Differences were
considered statistically signiﬁcant at the level of at least p ≤ 0.05.
3. Results & discussion
Conventionalmodels of carcinogenesis suggest that endothelial cells
are closely related with tumor perfusion. This concept has been chal-
lenged introducing the endothelium not only as a passive strong barrier
against cancer cells [32], but also as a stromal regulator during tumor
progression [33]. It is well established via the “seed and soil” notion
that cancer cells receive signals via growth factors that produce them-
selves or provided by the surrounding stroma, promoting a tumorigenic
phenotype.Fig. 2. Effect of BCC-CM onHUVECmigration. (A) Time-dependent wound healing assay for
(B) Representative images of wound healing assay for t = 0 h, upper panel and t = 6 h
Symbols mark the statistically signiﬁcant levels as follows: (*) and (**) indicate p b 0.05 and pIn this study,we evaluated howbreast cancer cells themselves signal
the stroma and speciﬁcally the endothelium for their beneﬁt and vice
versa. To start, using a chemokineticmodel, we evaluatedHUVECmigra-
tion by wound healing assay upon treatment with breast cancer cell-
derived conditioned media (BCC-CM). HUVEC exhibited a signiﬁcant
time-dependent reduced motility (Fig. 2A). This effect was evident
even at the short time of 6 h and especially upon treatmentwith CMde-
rived by the highly invasiveMDA-MB-231 breast cancer cells (30–40%).
It should be noted that wound closure depends on both migration and
proliferation of the cells, with the latter one affecting more the migra-
tion assay at higher time points. On the other hand, the migration of
breast cancer cells was up-regulated (15–30%) with the use of HUVEC
derived-CM in a time-dependent mode (Fig. 3A–C). The reduced motil-
ity of HUVEC observed by treatment with BCC-CMmay well be related
to the increased adhesive properties that in turn facilitate the formation
of “holes”within the endothelial front. This in combination with the in-
creased motility of breast cancer cells mediated by the HUVEC-derived
CM may further facilitate breast cancer cell progression.
The coordinated regulation of cell adhesion and cell motility in a
three-dimensional (3D)matrix, in otherwords, cell invasion, is the driv-
ing force in malignancies. It is well established that cancer cells in order
to establish distant metastasis invade the underlying stroma as a pre-
requisite. In an attempt to assess a tumor microenvironment mimetic
model, cell invasion was evaluated using a transwell chamber coated
with ECM matrix and as chemoattractant HUVEC-derived CM. As
shown in Fig. 4A, the invasive potential of the highly metastatic MDA-
MB-231 breast cancer cells through an ECM matrix was induced
(ca 50%) upon pre-activation of cancer cells by HUVEC-CM using as
chemo attractant either fetal bovine serum (data not shown) or
HUVEC-CM. However, the invasiveness of the weakly metastatic MCF-
7 cells was not affected (data not shown). Similar resultswere extracted
by another line of studies where the co-culture of endothelial cells and
MDA-MB-231 cells on a three-dimensional matrix, establishing direct
cell–cell contacts, resulted in increased breast cancer cell invasiveness
[28]. The signals transmitted by the coordinated interplay of cancer
and endothelial cells create an inﬂammatory environment and a pool
of growth factors that enhances contractile force generation and cyto-
skeletal remodeling of both parties, and thereby high transmigration
and invasion rates of the cancer cells [34–37]. The ability of cancer
cells to adhere to the endothelial cells is also of vital importance in
their line of crosstalk. In this study, we reported a highly adhesive pro-
ﬁle of the breast cancer cells on HUVEC monolayer in comparison to
commonplastic culture surface area (Fig. 4B). To strengthen this notion,
such high adhesion was further enhanced on HUVEC-produced ECM
(ca 60% for MCF-7 and 150% for the highly metastatic MDA-MB-231
breast cancer cells as compared to control cells) upon pre-treatment
with EDTA. On the other hand, treatment with hyaluronidase enzymethe time intervals of 2, 6 and 24 h. The results are expressed as % of wound closure;
, lower panel. The results represent mean ± SD of three independent experiments.
b 0.01, respectively, as compared to control cells and respective time interval.
Fig. 3. Effect of HUVEC-CM on BCCmigration.MDA-MB-231 cells (A), Time-dependent wound healing assay for the time intervals of 2, 6 and 24 h. The results are expressed as % of wound
closure; (B) Representative images of wound healing assay for t= 0 h, upper panel and t= 24 h, lower panel.MCF-7 cells (C), Time-dependent wound healing assay for the time intervals
of 2, 6 and 24h. The results are expressed as % ofwound closure; (D) Representative images ofwoundhealing assay for t=0h, upper panel and t=24h, lower panel. The results represent
mean ± SD of three independent experiments. Symbol marks the statistical signiﬁcant levels as follows: (*) indicates p b 0.05 as compared to control cells of its time interval.
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adherence is abolished (Fig. 4C). Collectively, these observations lead
us to the conclusion that cancer cells signal the endothelial cells' ECM
and vice versa, in such a way favoring the directional migration and
adherence of cancer cells.
Several emerging ﬁndings introduced cancer cells as transmitters and
generators of high contractile forces in order to transmigrate though the
endothelium [38]. The principal mediator of these forces is the acto-
myosin cytoskeleton, as cancer cells create a “leaky” endothelial front
and move along the endothelial acto-myosin ﬁlaments [39]. Speciﬁcally,
actin cytoskeleton serves asmigration grid for transendothelial migration
of cancer cells [40]. In the present study, the morphology of tubulin
networks in HUVEC was investigated by immunoﬂuorescence staining
using an antibody against α-tubulin. Untreated HUVEC possessed low
degree formation of tubulin ﬁlaments (Fig. 5). Treatment of HUVEC
with BCC-CM induced the formation of tubulin ﬁlaments as well as
banding of tubulin ﬁlaments. An overall solid cytoskeletal scaffold is
required from endothelial cells in order to hold the endothelial lining
against the transmigrating cancer cells. Gross morphological changes
were not observed in our experiments, whereas microtubule plasticity/
dynamics were indicated in correlation with altered endothelial cell
migration and the “leaky” endothelial barrier for cancer cells.
In another line of study, it was documented that the adhesion of
MDA-MB-231 to the vasculature originated in disruption of the
endothelial cell barrier via the degradation of the endothelial glycocalyx
[20]. Using real-time visualization, it was reported that the endothelium
is irreversibly damaged at the site of cancer cell transendothelial
migration [41]. Functional HUVEC properties are regulated by their
glycocalyx and especially ECM structure and ECM components'
expression [35]. Taking the above into account, we assayed the effect
of breast cancer cells on the expression of HUVEC expressed ECM
macromolecules.One endothelial glycocalyx component of vital importance is
hyaluronan as it plays a crucial role in the maintenance and enhance-
ment of vascular integrity through endothelial glycocalyx modulation,
caveolin-enriched microdomain regulation and interaction with endo-
thelial HA binding proteins [42–45]. Hyaluronan represent a very
large, linear glycosaminoglycan composed of 2000–25,000 repeated
disaccharide units composed of D-glucuronic acid and N-acetyl-D-
glucosamine. Cancer cells themselves as well as the stromal cells are
potent by the action of hyaluronidases and reactive oxygen species to
digest highmolecular HA into oligosaccharide-fragments of hyaluronan
[46–48]. However, its effects on angiogenesis and endothelial cell func-
tion depend on its molecular size as well as its concentration [46]. High
molecular weight HA (at concentrations N100 μg/ml) is anti-angiogenic,
documented to inhibit cell proliferation and disrupt conﬂuent endothelial
monolayers. In contrast, HA degradation products (4–25 disaccharides)
stimulate endothelial cell proliferation, migration and tube formation,
actions exerted via binding to speciﬁc HA receptors in particular, CD44
and Receptor for HA-Mediated Motility (RHAMM) [49]. In the present
study, following a sandwich protein binding solid phase assay, we
found that HUVEC-produced HA was signiﬁcantly induced by 39% when
treated with MDA-MB-231-CM as compared to the theoretical content
of control HUVEC plus MDA-MB-231 cells produced as mono-cultures
(Fig. 6Ai). This effect was evident also in the co-culture experimental
set as the HUVEC/MDA-MB-231 co-culture expressed higher amounts
of HA as compared to the separate monoculture of these cells
(Figure 6Aii). However, such up-regulation was not reported in the
case of MCF-7 breast cancer cell line of low invasive potential in both
experimental systems (Fig. 6A). It is worth noticing that in previous
data of our lab and others, we reported that the basal levels of HA in
the highly invasive breast cancer cell line MDA-MB-231 are ca 5-times
higher as compared to MCF-7 cells of the low invasive phenotype [50],
suggesting that the invasive potential of the breast cancer cells is
Fig. 4. Effect of HUVEC-CM on BCC invasion and adhesion. (A)MDA-MB-231 invasion; MDA-MB-231 cells were incubated for 24 h with or without HUVEC-CM and then harvested, re-
suspended in EGM-2medium, and loaded on the upper chamber, which contained a layer of ECMmatrix. HUVEC-CMwas used as a chemoattractant. Invasion time was 24 h. The results
represent mean ± SD of three independent experiments. Statistically signiﬁcant differences among the CM-treated and control cells are shown by (**) (p ≤ 0.01); (B) Experimental
approach concerning the BBCs adhesion assays. BBCs are loaded with red ﬂuorescent cell tracker and seeded to HUVEC cell monolayer; (C) Representative images of BCC adhesion
(with different seeding densities, low and high) to HUVEC monolayer at 3 h; (D) Adhesion of BCCs to HUVEC monolayer upon treatment with EDTA (buffer disassociating the cells
from the produced matrix) and hyaluronidase (degrading enzyme of HA). The results are expressed as number of adherent cells per microscope ﬁeld and represent mean ± SD of
three independent experiments. Symbol marks the statistically signiﬁcant levels as follows: (*) indicates p b 0.05 as compared to untreated control cells.
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HA by the endothelial cells induced by the cancers cells may also be in
part attributed to tumor-induced inﬂammation [51,52].Fig. 5. Effect of BCC-CMonHUVEC cytoskeleton. Immunoﬂuorescence stainingwas performed f
of tubulin ﬁlaments, as well as banding of tubulin ﬁlaments were observed upon treatment wiThemRNA expression of the other critical co-player, the HA receptor
CD44 standard isoform (CD44s), was ca 2.5 and 1.8-times over-
expressed upon treatment with MDA-MB-231 and MCF-7 cell-derivedorα-tubulin (red) and nuclei (blue) in HUVEC after permeabilization. Increased formation
th BCC-CM (shown in arrowheads).
Fig. 6. Effect of BCCs onHUVEC on the expression of HA, CD44 andHAS2. (A)HA concentration in culturemedia of HUVEC treatedwith BCC-CMusing (i) conditionedmedia and (ii) the co-
culture experimental approach. Statistically signiﬁcant differences among the treated and control cells are shown by (#) (p≤ 0.001) and (**) (p≤ 0.01); (B) Real time-PCR analysis of the
expression of CD44 in HUVEC treated with BCC-CM using (i) conditioned media and (ii) the co-culture experimental approach; (C) Real time-PCR analysis of the expression of HAS2 in
HUVEC treatedwith BCC-CMusing (i) conditionedmedia and (ii) co-culture experimental approach. The results representmean± SD of three independent experiments. Statistically sig-
niﬁcant differences among the treated and control cells are shown by (*) (p ≤ 0.05) and (**) (p ≤ 0.01).
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following the co-culture experimental approach, a much lower but sig-
niﬁcant overexpression (ca 20–30% increase) was noted (Fig. 6Bii). It is
worth noting that the HA synthase HAS2 in HUVEC was substantially
up-regulated by cancer cells in both culture models used (Fig. 6C). The
effects induced from the highly metastatic MDA-MB-231 cells are in
all cases higher as compared to the low metastatic MCF-7 cells. Due to
its biological nature HA contributes to the formation of HA-dependent
pericellular matrix, contributing to cell adhesion/de-adhesion and cellmorphological changes [53]. In this study, no apparent changes in HA-
dependent pericellular matrix were observed, visualized by particle
exclusion assay (data not shown). To strengthen this observation, it is
documented in the literature that overexpression of HAS2 in vascular
smooth muscle cells resulted in low pericellular HA, leading though to
diminished growth and migratory phenotype as well as increased
monocyte adhesion [51].
As described above (Fig. 4B), when the HUVEC cell monolayer was
pretreated with hyaluronidase the increased adhesion of cancer cells
2556 C. Gialeli et al. / Biochimica et Biophysica Acta 1840 (2014) 2549–2559was abolished, indicating that cancer cell adhesion is partly attributed to
HA (Fig. 4B). Endothelial HA expression creates an inﬂammatory envi-
ronment and vice versa resulting in CD44/HA primary adhesion [54].
It is worth mentioning the important role of CD44-crosslinking in
integrin-mediated adhesion and transendothelial migration of breast
cancer cells [41,55].
Cell adhesive properties that cells exhibit to each other, their extra-
cellular matrices and other surfaces are mediated by a variety of mem-
brane proteins collectively known as cell adhesion molecules (CAMs).
The progression of tumor malignancies is often associated with alter-
ations in CAM proﬁle, introducing CAMs' important role in cancer
metastasis. The intercellular cell adhesion molecule-1 (ICAM-1) and
vascular endothelial cell adhesion molecule-1 (VCAM-1) have been im-
plicated in the process of cancer induced-inﬂammation/oxidate stress
[56]. In the present study, we reported substantially up-regulated
gene expression levels of these adhesion molecules in HUVEC by breast
cancer cells in both culture models used. Speciﬁcally, VCAM and ICAM
expression in HUVEC revealed an approximately 60-fold and 20-fold,
respectively increase induced by MDA-MB-231 CM, whereas MCF-7
CM exhibited a lower extent effect (Fig. 7Ai–Bi). In the co-culture exper-
imental approach, a lower but signiﬁcantly signiﬁcant up-regulation
was also observed (Fig. 7Ai–Bi). Several data revealed an implication
of ICAM-1 and VCAM-1 in tumor cell extravasation and VCAM-1 in
cell adhesion [57]. Leukocytes have often been used to model the
interactions between circulating tumor and endothelial cells [58]. In
the literature, it is highlighted that HA is the principal modulator of
leukocyte–endothelial cell interaction, including events like inﬂamma-
tory response upregulation of HAS2, CD44, and other adhesive mole-
cules (ICAM-1, E-selectin, VCAM-1) [59].
The proteolytic cascade is highly implicated in the orchestrated
alterations of endothelial cell interactions with the cancer cells as wellFig. 7. Effect of BCCs onHUVEC on the expression of the adhesionmolecules, VCAMand ICAM. (
(i) conditioned media and (ii) co-culture experimental approach; (B) Real time-PCR analysis of
(ii) the co-culture experimental approach. The results represent mean± SD of three independe
shown by (*) (p ≤ 0.05) and (**) (p ≤ 0.01).aswith the components of the underlying basementmembrane. Matrix
metalloproteinases (MMPs) have the ability to degrade components
of the ECM, thus inﬂuencing cell–cell and cell–matrix interactions,
crucial in the transition of endothelial cell phenotype associated with
angiogenesis [60,61]. However, MMPs' contribution to angiogenesis is
time-related. Here, we reported a downregulation in the expression of
MMP-2 and membrane-type-1-MMP (MT1-MMP) in both culture
models tested by the action of BCCs (Fig. 8A–B). This reduced remodel-
ing ability of HUVEC induced by cancer cells may be due to themorpho-
logical changes of HUVEC during BCCs' trans-endothelial migration. In
the literature it is reported that there is a direct correlation of the levels
of MMPs with the extent of cell–cell and cell–ECM contacts that HUVEC
form. For example, down-regulation of MMP-2 and MMP-9 is docu-
mented when HUVEC undergo morphological changes [62].
26S proteasome is a macromolecular multi-subunit complex re-
sponsible for recognizing, unfolding, and ultimately destroying proteins
[63]. In a recent review of our research groupwe highlighted the impor-
tance of targeting proteasome and indirectly affecting ECM [30]. The
proteasome possesses multiple endopeptidase activities including
chymotrypsin-like (CT-L), peptidyl glutamyl peptide hydrolase-like
(PGPH-L) and trypsin-like (T-L), which are localized on β5, β1 and β2
catalytic subunits, respectively [64]. We assayed the effect of BCC-CM
on the expression and activity of endothelial β5 proteasome subunit.
Our results indicated a statistically signiﬁcant increase of β5 expression
subunit (ca 50%) especially by MDA-MB-231 CM, a result that is also
correlated with increased proteasome activity (Fig. 9). There are many
evidences that the ubiquitin proteasome system is implicated in the de-
velopment of endothelial (dys)function, which is reﬂected as enhanced
26S proteasome activity, an accelerated degradation of endothelial-
protective molecules [65]. In another line of studies they reported that
inhibition of proteasome resulted in diminished expression of HASA) Real time-PCR analysis of the expression of VCAM inHUVEC treatedwith BCC-CMusing
the expression of ICAM in HUVEC treated with BBCs-CM using (i) conditioned media and
nt experiments. Statistically signiﬁcant differences among the treated and control cells are
Fig. 8. Effect of BCCs on HUVEC on the expression of the proteolytic enzymes, MMP-2 andMT1-MMP. (A) Real time-PCR analysis of the expression ofMMP-2 in HUVEC treatedwith BCC-
CM using (i) conditioned media and (ii) the co-culture experimental approach. (B) Real time-PCR analysis of the expression of MT1-MMP in HUVEC treated with BBC-CM using (i) con-
ditioned media and (ii) the co-culture experimental approach. The results represent mean± SD of three independent experiments. Statistically signiﬁcant differences among the treated
and control cells are shown by (*) (p ≤ 0.05) and (**) (p ≤ 0.01).
2557C. Gialeli et al. / Biochimica et Biophysica Acta 1840 (2014) 2549–2559and subsequent expression of HA. So in our system, we reported an up-
regulation of the proteasome expression levels and activity in correla-
tionwith observed altered endothelial cell properties and the increasedFig. 9. Effect of BCC-CM on HUVEC-expressed proteasome. (A) Real time-PCR analysis of
the expression of β-5 proteasome subunit in HUVEC treated with BCC-CM; (B) Protea-
some activity of β-5 subunit of HUVEC treated with BBC-CM. The results represent mean
± SD of three independent experiments. Statistically signiﬁcant differences among the
BBC-CM-treated and control cells are shown by (*) (p ≤ 0.05) and (**) (p ≤ 0.01).HA levels and HAS2 expression. However, it must be noted that
proteasome-dependent synthesis of hyaluronan may be a cell type-
and context-speciﬁc process.4. Conclusions
The impact of endothelium on cancer cells and vice versa is still to a
great degree undeﬁned, and hence under investigation. How exactly the
endothelium functions under these processes is still elusive. Moreover,
the mechanisms by which cancer cells can transmigrate through the
endothelial lining are not well understood. Therefore in this study we
evaluated the effects of breast cancer cells on the expression and prop-
erties of endothelial cells. For this purpose two experimental cell culture
approaches were used; one involves the use of CM media from HUVEC
and BCCs and the other the co-culture of these two cell population
through a transwell system. It is worth noting that the gene expression
of the matrix macromolecules evaluated in this study are signiﬁcantly
modiﬁed either by the action of breast cancer cell conditioned media
or by the co-culture models. However, the protein expression and its
activity in this study haven't been evaluated, the altered gene expres-
sion proﬁle further highlights and establishes the importance of the dy-
namicmatrix network on cell properties. In this line, we found that such
paracrine interactions affect the behavior of endothelial cells.Migration,
adhesion and invasion are among the functional properties affected. It is
therefore concluded that the breast cancer cell secreted effectors are of
crucial importance to signal the endothelial cells and to modify their
glycocalyx expression and properties. The upregulation of endothelium
adhesion molecules and proteosomal activity, reorganization of the en-
dothelial cytoskeleton, aswell as Src-mediated disruption of endothelial
VE-cadherin-b-catenin cell–cell adhesions summarize thedriving forces
of cancer cells to the endothelium in order to overpass endothelial barri-
er. An overview of the results obtained in this study is depicted in Fig. 10.
Fig. 10.Overall interplay of breast cancer cells and endotheliumdepicted in this study. Breast cancer cells and endothelium establish a close communication. Breast cancer cells, at one part,
exhibit increased directional migration, invasion through the ECM and increased adhesion to the endothelium induced by the endothelial cells. On the other hand, endothelial cell migra-
tion is diminished and their cytoskeleton is altered mediated by BCCs in order to create a loose endothelial barrier for the transendothelial migration of cancer cells. The endothelial
glycocalyx is also adapted for this purpose. HA, its receptor CD44 and enzyme synthase HAS2 expression is up-regulated, whereas MMP-2, MT1-MMP are down-regulated. At last, cancer
cells induce endothelial proteasome expression and activity, resulting in a dysfunctional endothelium.
2558 C. Gialeli et al. / Biochimica et Biophysica Acta 1840 (2014) 2549–2559These observations will force new studies in the ﬁeld to evaluate in detail
the underlying signaling mechanisms and open a new area to design
novel drugs for pharmacological targeting of breast cancer at the ECM
level.
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